Successful Use of Intraperitoneal Daptomycin in the Treatment of Vancomycin-Resistant Enterococcus Peritonitis

Huen, Sarah C.; Hall, Isaac E.; Topal, Jeffrey; Mahnensmith, Rex L.; Brewster, Ursula C.; Abu‐Alfa, Ali K.

doi:10.1053/j.ajkd.2008.12.017

Cited by 40 publications

(41 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The successful use of daptomycin in PD-related peritonitis has been previously reported [15,16,17]. Here, we further show that daptomycin eradicates biofilm-associated foreign body infections and that it exerts synergistic effects with rifampin.…”

Section: Discussionsupporting

confidence: 79%

“…Bahte et al [15] have reported the therapeutic plasma concentration of daptomycin after single IP daptomycin administration in a peritonitis patient. Huen et al [16] and Hassoun et al [17] have successfully used IP daptomycin to treat cases of vancomycin-resistant enterococci peritonitis. In our case, IP daptomycin at 20 mg/l in 2.5% dextrose low calcium (2.5 mEq/l) dialysate every 4 h and 7.5% icodextrin dialysate every 12 h exerted the same therapeutic effects as reported by Huen et al [16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful Salvage of Peritoneal Catheter in Unresolved Methicillin-Resistant <i>Staphylococcus aureus</i> Peritonitis by Combination Treatment with Daptomycin and Rifampin

Lin

Liu

et al. 2011

Blood Purif

View full text Add to dashboard Cite

Peritoneal dialysis patients are at an increased risk of Gram-positive organism infections because of disrupted skin barrier function, presence of a peritoneal catheter, and a deficient immunological system. In particular, the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections is clinically challenging. Herein, we present a case of MRSA peritonitis that showed no response to a 14-day treatment with intraperitoneal vancomycin. To overcome unresponsiveness to vancomycin, we shifted the regimen to intraperitoneal daptomycin (given every 6 h through manual peritoneal dialysate exchanges) and oral rifampin (300 mg twice daily). The peritonitis resolved without sequelae or relapse. We suggest daptomycin and rifampin as an alternative combination therapy for MRSA infections that may otherwise remain unresolved.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Successful Salvage of Peritoneal Catheter in Unresolved Methicillin-Resistant <i>Staphylococcus aureus</i> Peritonitis by Combination Treatment with Daptomycin and Rifampin

Lin

Liu

et al. 2011

Blood Purif

View full text Add to dashboard Cite

show abstract

“…Because our patient wanted to remain on PD and because she showed clinical improvement after linezolid treatment, we decided to continue the antibiotic therapy without catheter removal. Only two previous reports have described cases of VrE peritonitis treated with IP daptomycin (10) or IV linezolid (13) without removal of the PD catheter. It therefore remains unclear whether the catheter must be removed in case of VrE peritonitis.…”

Section: Discussionmentioning

confidence: 99%

“…Vancomycin-resistant Enterococcus (VrE) has been reported, but remains an uncommon causative organism of peritonitis in PD patients (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13). The available data about the appropriate treatment for VrE peritonitis are limited.…”

Section: Disclosuresmentioning

confidence: 99%

Successful Treatment of Vancomycin-Resistant Enterococcus Peritonitis Using Linezolid Without Catheter Removal in a Peritoneal Dialysis Patient

Song

Seo

Kwon

et al. 2014

Peritoneal Dialysis International

View full text Add to dashboard Cite

“…Although nearly all daptomycin in the peritoneal cavity is unbound, we cannot confidently recommend intravenous daptomycin for peritonitis at this time given the discordance of reported effective AUC/MIC ratios for daptomycin (15,18 -20), the lack of a pharmacodynamic target at the tissue level (26), and the lack of data regarding how inflammation would affect concentrations in the peritoneum. Intraperitoneal (IP) administration of daptomycin is a possible alternative to IV administration (27)(28)(29). However, further pharmacokinetic, clinical, and stability studies are necessary before IP administration of daptomycin is adopted as the standard of practice for peritonitis (8).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis

Cardone

Lodise²,

Patel³

et al. 2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Summary Background and objectives This study sought to (1) characterize the pharmacokinetic (PK) profile of intravenous (IV) daptomycin among patients receiving continuous ambulatory peritoneal dialysis (CAPD); (2) identify optimal IV CAPD dosing schemes; and (3) determine extent of daptomycin penetration into the peritoneal space after IV administration. Design, setting, participants, & measurements A PK study was conducted among eight CAPD patients. Population PK modeling and Monte Carlo simulation (MCS) were used to identify CAPD dosing schemes providing efficacy and toxicity plasma profiles comparable with those obtained from MCS using the daptomycin population PK model derived from patients in the Staphylococcus aureus bacteremia-infective endocarditis (SAB-IE) study. The primary efficacy exposure target was the area under the curve (AUC). For toxicity, the goal was to identify CAPD dosing schemes that minimized plasma trough concentrations in excess of 24.3 mg/L. Finally, peritoneal cavity penetration was determined. Results Administration of IV daptomycin 4 or 6 mg/kg, depending on indication, every 48 h was identified as the optimal CAPD dosing scheme. This regimen provided cumulative (AUC0–48) and daily partitioned (AUC0–24h and AUC24–48h) plasma AUC values similar to the SAB-IE or “typical patient” simulations. In addition, the proportion of patients likely to experience an elevated trough concentration in excess of 24.3 mg/L was similar between every 48 h CAPD dosing and the referent group. Penetration into the peritoneal cavity was 6% of plasma. Conclusions Daptomycin 4 or 6 mg/kg, on the basis of indication, IV every 48 h was found to be the optimal IV CAPD dosing scheme.

show abstract

Successful Use of Intraperitoneal Daptomycin in the Treatment of Vancomycin-Resistant Enterococcus Peritonitis

Cited by 40 publications

References 10 publications

Successful Salvage of Peritoneal Catheter in Unresolved Methicillin-Resistant <i>Staphylococcus aureus</i> Peritonitis by Combination Treatment with Daptomycin and Rifampin

Successful Salvage of Peritoneal Catheter in Unresolved Methicillin-Resistant <i>Staphylococcus aureus</i> Peritonitis by Combination Treatment with Daptomycin and Rifampin

Successful Treatment of Vancomycin-Resistant Enterococcus Peritonitis Using Linezolid Without Catheter Removal in a Peritoneal Dialysis Patient

Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis

Contact Info

Product

Resources

About